Obsessive-Compulsive Disorder with predominance of obsessive ideas or ruminations
Conditions
Interventions
A total of 30 patients will receive drug treatment with a serotonin reuptake inhibitor, preferably Sertraline hydrochloride. The drug should be administered orally, during the first week at a dose of
F42.2
Sponsors
Instituto de Psiquiatria
Instituto de Psiquiatria
Eligibility
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Male or female aged between 18 and 50 years; Main diagnosis of Obsessive-Compulsive Disorder according to DSM-5; Y-BOCS score = 16; No psychotropic medication used in the last 6 weeks; No behavioral therapy or response prevention exposure focusing on Obsessive-Compulsive Disorder in the past 6 weeks; Able to tolerate a 1-week treatment-free period; and Able to provide informed consent.
Exclusion criteria
Exclusion criteria: Lifetime diagnosis of psychotic disorder, bipolar disorder, anorexia nervosa, autistic spectrum disorder with IQ<80, Tourette's disorder; Current chronic tic disorder (current = within the last 12 months); Disorders related to the use of current substances, including nicotine (current = within the last 12 months); Current eating disorder or bulimia (current = within the last 12 months); Acute risk of suicide. Pregnant women; Medical or neurological problems (including head trauma with loss of consciousness); Presence of metal devices on the body or dental appliances; IQ<80; Cigarette use: more than 5 per day; Alcohol use: more than 2 drinks a day for women and more than 3 drinks a day for men; Cannabis use: more than once a week.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find variation in brain volumes in the orbitofrontal cortex, anterior cingulate, striatum, dorsolateral and dorsomedial prefrontal cortex, insula, thalamus, hippocampus, pituitary gland, amygdala and cerebellum, obtained by means of structural NMR, among individuals responders on sertraline for 12 weeks compared with non-responders. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to find variation in structural connectivity, represented by measurements of fractional anisotropy in the corpus callosum, internal capsule, white matter in the area superolateral to the right caudate, bilateral cingulate, superior longitudinal fasciculus and inferior longitudinal fasciculus, obtained by means of DTI (Diffusion tensor imaging) among responders to sertraline treatment for 12 weeks compared with non-responders;It is expected to find variation in functional connectivity, represented by activation and connectivity patterns in frontal-striatal (central executive), parietal, occipital, cerebellar and insula-limbic (salient) networks, obtained through functional NMR at rest, among responders to sertraline treatment for 12 weeks compared with non-responders. | — |
Countries
Brazil, India, South Africa
Contacts
Public ContactRoseli Shavitt
Instituto de Psiquiatria
Outcome results
None listed